Literature DB >> 8155996

Mechanism of eosinophil infiltration in the patient with subcutaneous angioblastic lymphoid hyperplasia with eosinophilia (Kimura's disease). Mechanism of eosinophil chemotaxis mediated by candida antigen and IL-5.

N Terada1, A Konno, K Shirotori, T Fujisawa, J Atsuta, R Ichimi, Y Kikuchi, S Takaki, K Takatsu, K Togawa.   

Abstract

Kimura's disease is a chronic granulomatous disease of unknown etiology. Although eosinophilia is one of the characteristic features in this disease, little is known about the mechanism of eosinophilia. In the present study it was demonstrated that interleukin-5 (IL-5) was produced and released from the site of a granuloma and lymph nodes after stimulation with candida antigen. It was also shown that peripheral blood eosinophils from patients with Kimura's disease contained a large proportion of hypodense eosinophils and that their viability was prolonged. These results strongly suggest that locally produced IL-5 induced by candida antigen contributes to the eosinophilia in this disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8155996     DOI: 10.1159/000236740

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  3 in total

Review 1.  Selected topics on lymphoid lesions in the head and neck regions.

Authors:  Wesley O Greaves; Sa A Wang
Journal:  Head Neck Pathol       Date:  2011-02-03

Review 2.  T helper cell dichotomy to Candida albicans: implications for pathology, therapy, and vaccine design.

Authors:  L Romani; E Cenci; A Menacci; F Bistoni; P Puccetti
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

3.  Mucoepidermoid carcinoma of parotid gland and membranous nephropathy - differentiation between sclerosing mucoepidermoid carcinoma with eosinophilia and Kimura's disease.

Authors:  Hayato Fujioka; Tsutomu Koike; Teruhiko Imamura; Kota Kakeshita; Hidenori Yamazaki; Hideharu Abe; Takahiko Nakajima; Koichiro Kinugawa
Journal:  BMC Nephrol       Date:  2020-08-26       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.